Top Most 27+ What Is Ca 19 9
-
1.CA 19-9 Blood Test (Pancreatic Cancer): MedlinePlus Medical Test
This test measures the amount of a protein called CA 19-9 in the blood. High levels of CA 19-9 can be a sign of pancreatic cancer, other cancers, or certain noncancerous disorders. The test is often used to monitor treatment for pancreatic cancer. Learn more.
View more » -
2.CA19-9
The CA 19-9 Radioimmunoassay (RIA) is a simple blood test that measures the level of tumor-associated antigens found in the blood. CA 19-9 associated antigen levels are elevated in many patients with pancreatic cancer. Learn what the test results mean and how the test is performed.
View more » -
3.CA19-9
The CA 19-9 Radioimmunoassay (RIA) is a simple blood test that measures the level of tumor-associated antigens found in the blood. CA 19-9 associated antigen levels are elevated in many patients with pancreatic cancer. Learn what the test results mean and how the test is performed.
View more » -
4.CA19-9
The CA 19-9 Radioimmunoassay (RIA) is a simple blood test that measures the level of tumor-associated antigens found in the blood. CA 19-9 associated antigen levels are elevated in many patients with pancreatic cancer. Learn what the test results mean and how the test is performed.
View more » -
5.CA19-9
The CA 19-9 Radioimmunoassay (RIA) is a simple blood test that measures the level of tumor-associated antigens found in the blood. CA 19-9 associated antigen levels are elevated in many patients with pancreatic cancer. Learn what the test results mean and how the test is performed.
View more » -
6.Content - Health Encyclopedia - University Of Rochester Medical Center
-
7.CA 19-9
Learn more about CA 19-9, a protein useful for evaluating cancers in the colon, pancreas, stomach, or bile duct, as well as other noncancerous conditions.
View more » -
8.Cancer Antigen 19-9
What does CA 19-9 testing tell you about your diagnosis? Learn how the test is conducted and used and what role it plays in cancer and other conditions.
View more » -
9.Cancer Antigen 19-9
What does CA 19-9 testing tell you about your diagnosis? Learn how the test is conducted and used and what role it plays in cancer and other conditions.
View more » -
10.Cancer Antigen 19-9
What does CA 19-9 testing tell you about your diagnosis? Learn how the test is conducted and used and what role it plays in cancer and other conditions.
View more » -
11.Cancer Antigen 19-9
What does CA 19-9 testing tell you about your diagnosis? Learn how the test is conducted and used and what role it plays in cancer and other conditions.
View more » -
12.CA19 - Overview: Carbohydrate Antigen 19-9 (CA 19-9), Serum
-
13.CA 19-9: Reference Range, Interpretation, Collection And Panels
Cancer antigen 19-9 (CA 19-9) is used to help differentiate between cancer of the pancreas and other conditions, as well as to monitor treatment response and recurrence. The reference range of serum CA 19-9 is less than 37 U/mL.
View more » -
14.CA 19-9: Reference Range, Interpretation, Collection And Panels
Cancer antigen 19-9 (CA 19-9) is used to help differentiate between cancer of the pancreas and other conditions, as well as to monitor treatment response and recurrence. The reference range of serum CA 19-9 is less than 37 U/mL.
View more » -
15.CA 19-9: Reference Range, Interpretation, Collection And Panels
Cancer antigen 19-9 (CA 19-9) is used to help differentiate between cancer of the pancreas and other conditions, as well as to monitor treatment response and recurrence. The reference range of serum CA 19-9 is less than 37 U/mL.
View more » -
16.CA 19-9: Reference Range, Interpretation, Collection And Panels
Cancer antigen 19-9 (CA 19-9) is used to help differentiate between cancer of the pancreas and other conditions, as well as to monitor treatment response and recurrence. The reference range of serum CA 19-9 is less than 37 U/mL.
View more » -
17.NCI Dictionary Of Cancer Terms
NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine.
View more » -
18.Cancer Antigen 19-9 | Labcorp
-
19.Cancer Antigen 19-9 | Labcorp
-
20.Cancer Antigen 19-9 | Labcorp
-
21.Cancer Antigen 19-9 | Labcorp
-
22.002261: Carbohydrate Antigen (CA) 19-9 | Labcorp
Labcorp test details for Carbohydrate Antigen (CA) 19-9
View more » -
23.Carbohydrate Antigen 19-9 Elevation Without Evidence Of Malignant Or Pancreatobiliary Diseases - Scientific Reports
Although carbohydrate antigen 19-9 (CA 19-9) may be elevated in benign diseases, elevated CA 19-9 may cause a fear of cancer and unnecessary follow-up studies. Research on how to approach systematically in this case is very limited. The purpose of this study was to analyze the clinical features and the causes of CA 19-9 elevation without evidence of malignant or pancreatobiliary diseases. We retrospectively reviewed the medical records of patients who had CA 19-9 elevation (≥80 U/mL) and were found to be unrelated to cancer after follow-up. After exclusion, 192 patients were included in this study. The median level of CA 19-9 was 136.5 U/mL. The causes of CA 19-9 elevation were determined in 147 (76.6%) patients, and that was unknown in 45 (23.4%). The estimated causative diseases were hepatic diseases in 63 patients, pulmonary diseases in 32, gynecologic diseases in 38, endocrine diseases in 13, and spleen disease in 1. Of 45 patients with unknown cause, 35 had normalization of CA 19-9 and 10 had persistently elevated CA 19-9. In conclusion, CA 19-9 elevation without malignancies or pancreatobiliary diseases should be systematically evaluated and followed up. We suggest an algorithm to investigate the causes and follow up these patients.
View more » -
24.CA19-9 For Detecting Recurrence Of Pancreatic Cancer - Scientific Reports
CA19-9 values are regularly measured in patients with pancreatic cancer. Certainly, its potential as a biomarker has been compromised by false negative results in CA19-9 negative patients and false positive results in benign pancreatico-biliary diseases. For detection of PDAC recurrence, however, CA19-9 might play an important role. The aim of this study is to analyze the accuracy of CA19-9 for detecting recurrence of pancreatic cancer. All included patients were treated either at the University Medical Center Goettingen, or at the Department of Interdisciplinary Oncology and Pneumonology, DRK-Kliniken Nordhessen, Kassel. We analyzed data of 93 patients with pancreatic cancer in the training set and 41 in the validation set, both retrospectively. Pre- and postoperative CA19-9 values and results of imaging techniques were compared. We performed ROC-analysis. The association between longitudinally measured CA19-9 values and relapse was studied with a joint model between a random effects model for the longitudinal CA19-9 measurements and a Cox proportional hazards models for the survival data. In the test set (n = 93 patients) the median follow-up time was 644 days (22 months). Overall, 71 patients (76.3%) developed recurrence during follow-up. Patients with CA19-9 values of <10kU/l were considered as CA19-9 negative patients (n = 11) and excluded from further analysis. Among the rest, approximately 60% of the patients showed significantly elevated CA19-9 prior to detection of recurrence by imaging techniques. Recurrence was shown by 2.45 times elevated CA19-9 values with 90% positive predictive value. In the validation set, 2.45 times elevated CA19-9 values showed recurrence with 90% sensitivity and 83,33% specificity, with an area under the curve of 95%. Based on measured CA19-9 values during follow-up care, the joint model estimates in recurrence-free patients the probability of recurrence-free survival. CA19-9 elevation is an early and reliable sign for PDAC recurrence. On the strength of a very high accuracy in CA19-9 positive patients, it should be considered to use CA19-9 for therapy decision even without a correlate of imaging technics. Using the joint model, follow-up care of PDAC patients after curative therapy can be stratified.
View more » -
25.Elevated Serum CA19-9 Level Is A Promising Predictor For Poor Prognosis In Patients With Resectable Pancreatic Ductal Adenocarcinoma: A Pilot Study - World Journal Of Surgical Oncology
Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human cancers. Several studies have reported that the carbohydrate antigen 19-9 (CA19-9) level is a useful marker for predicting the prognosis for PDAC after resection. However, the cutoff value of CA19-9 used to predict prognosis varied among these reports. The aims of this study were to evaluate whether the serum CA19-9 level is a significant predictor for survival and to determine the optimal cutoff value of CA19-9 for predicting prognosis. Methods A total of 120 consecutive patients who underwent surgery for potentially resectable primary PDAC were retrospectively analyzed. The variables included the following: age, sex, the location of the tumor, the maximal tumor size, the histological differentiation, the margin status, the tumor stage, serum CA19-9 levels, and serum total bilirubin (TBil) levels. Results The overall 1-year survival rate was 62.5%. The receiver operating characteristic (ROC) curve indicated a significant result for the level of CA19-9 in predicting death within 1 year after surgery (Area under the curve (AUC), 0.612; 95% confidence interval (CI), 0.505-0.720; P = 0.040). The optimal cutoff point was 338.45 U/mL (sensitivity, 60.0%; specificity, 66.7%; accuracy, 64.2%). The strongest univariate predictor among the categorized CA19-9 values was CA19-9 greater than or equal to 338.45 U/mL. In the multivariate Cox proportional hazards mode analysis, the serum CA19-9 level, age and the histological differentiation were significant independent prognostic factors that were associated with the overall survival. Conclusions The preoperative elevated CA19-9 level is a promising independent factor for predicting a poor prognosis in PDAC, and the optimal cutoff value is 338.45 U/mL.
View more » -
26.Low Carbohydrate Antigen 19-9 (CA 19-9) Levels In A Patient Highly Suspected Of Having Caput Pancreas Tumor
Pancreatic cancer is the seventh leading cause of cancer-related mortality worldwide and the eleventh most common cause of cancer-related death in Indonesia. In pancreatic cancer, rapid and early diagnosis is crucial. Carbohydrate antigen 19-9 (CA 19-9), the most sensitive and specific tumor marker for pancreatic cancer, may help in diagnosing and determining prognosis; however, some populations do not express CA 19-9. Cases of low CA 19-9 may occur in populations with Lewis⍺-β- genotype. These populations are not able to express Lewis antigen and CA 19-9; therefore, CA 19-9 investigation cannot be used for diagnostic and therapeutic measures. In patients highly suspicious of pancreatic cancer where CA 19-9 levels are low, alternative tumor markers such as CA 125 and carcinoembryonic antigen or a combination of various tumor markers can be used to increase sensitivity and specificity in diagnosing pancreatic cancer. A 70-year-old man presented with a complaint of worsening abdominal pain for the last two days. The patient had dark-yellow urine and pale stool. Abdominal ultrasonography and computed tomography scan showed a mass on the head of the pancreas, which was highly suspicious of pancreatic cancer.
View more » -
27.An Extremely Increased CA19-9 Level Due To Common Bile Duct Stone: A Case Report
An extremely increased CA19-9 level due to common bile duct stone: a case report
View more »